Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 6/20 | 0.38 |
| ▸ | BRD2 | P25440 | 6/20 | 0.38 |
| ▸ | BRD3 | Q15059 | 6/20 | 0.38 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | TAF1 | P21675 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | EP300 | Q09472 | 1/20 | 0.38 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.38 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.38 |
| ▸ | TAF1L | Q8IZX4 | 1/20 | 0.38 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.38 |
| ▸ | BRWD1 | Q9NSI6 | 1/20 | 0.38 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.37 |
| ▸ | SPTLC2 | O15270 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4129049 | 1.00 | POLB (0.39) | POLBBRD4BRD2BRD3TRIM24 | |
| SCHEMBL221467 | 0.85 | BRD4 (0.48) | BRD4BRD2BRD3TRIM24CYP3A4 | |
| SCHEMBL221468 | 0.85 | BRD4 (0.48) | BRD4BRD2BRD3TRIM24CYP3A4 | |
| SCHEMBL221466 | 0.85 | BRD4 (0.48) | BRD4BRD2BRD3TRIM24CYP3A4 | |
| SCHEMBL4196392 | 0.81 | CHRNB2 (0.38) | BRD4BRD2BRD3CHRNB2CHRNA4 | |
| SCHEMBL6514954 | 0.81 | CHRNB2 (0.38) | BRD4BRD2BRD3CHRNB2CHRNA4 | |
| SCHEMBL4196389 | 0.81 | CHRNB2 (0.38) | BRD4BRD2BRD3CHRNB2CHRNA4 | |
| SCHEMBL6514956 | 0.81 | CHRNB2 (0.38) | BRD4BRD2BRD3CHRNB2CHRNA4 | |
| SCHEMBL4196397 | 0.81 | CHRNB2 (0.38) | BRD4BRD2BRD3CHRNB2CHRNA4 | |
| SCHEMBL5501901 | 0.79 | BRD4 (0.36) | POLBBRD4HTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110229104-B | Method for synthesizing tetrahydroquinoline compound by catalyzing arylamine and alpha-keto ester with cyclopentadienyl titanium/Bronsted acid | 陕西师范大学 | 2022-06-07 | — | — | CN | disclosed |
| CN-108017580-B | Method for synthesizing 1,2,3, 4-tetrahydroquinoline compound by decarboxylation of amino acid under catalysis of visible light | 河南大学 | 2021-02-02 | — | — | CN | disclosed |
| US-20090181966-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-07-16 | — | — | US | disclosed |
| US-7504508-B2 | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-7211672-B2 | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-05-01 | — | — | US | disclosed |
| US-20060106061-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. | 2006-05-18 | — | — | US | disclosed |
| US-20050256158-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. | 2005-11-17 | — | — | US | disclosed |
| US-20040082609-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256158-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | PTGDR2, LTB4R2, CYSLTR2 | POLB 4317/4885BRD4 1768/4885BRD2 651/4885 |
| US-20060106061-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | PTGDR2, LTB4R2, CYSLTR2 | POLB 4199/4885BRD4 1267/4885BRD2 544/4885 |
| US-20090181966-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | PTGDR2, LTB4R2, CYSLTR2 | POLB 4317/4885BRD4 1768/4885BRD2 651/4885 |
| US-20040082609-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | PTGDR2, PTGDR, LTB4R2 | POLB 3769/4885BRD4 1699/4885BRD2 736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.